Jan Leschly has resigned as president of Squibb Corp., saying his personal goals "are not realistic" under the company's merger with Bristol-Myers Co.
"The combination of the two companies makes it difficult for me personally to realize my own career objectives," said Leschly. "The near-term personal goals that I had hoped to achieve at Squibb as an independent company are not realistic within the same time frame with Bristol-Myers Squibb."
Squibb, based in Princeton, N.J., became a wholly owned subsidiary of Bristol-Myers Squibb Co. under a merger approved by stockholders last week that created the world's second-largest pharmaceutical firm.
With Leschly's resignation, Bristol-Myers Squibb announced a number of organizational changes.
Reporting directly to Richard M. Furlaud, president of Bristol-Myers Squibb and former chairman and chief executive of Squibb Corp., will be William T. Comer, who will assume the new position of president, Bristol-Myers Pharmaceutical Research & Licensing Group, and Edgar Haber, president, Squibb Institute for Medical Research.